紫外線(日光)角化症(Actinic (Solar) Keratosis)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Actinic (Solar) Keratosis Overview 9
Therapeutics Development 10
Pipeline Products for Actinic (Solar) Keratosis – Overview 10
Pipeline Products for Actinic (Solar) Keratosis – Comparative Analysis 11
Actinic (Solar) Keratosis – Therapeutics under Development by Companies 12
Actinic (Solar) Keratosis – Therapeutics under Investigation by Universities/Institutes 14
Actinic (Solar) Keratosis – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Actinic (Solar) Keratosis – Products under Development by Companies 19
Actinic (Solar) Keratosis – Products under Investigation by Universities/Institutes 21
Actinic (Solar) Keratosis – Companies Involved in Therapeutics Development 22
3M Drug Delivery Systems 22
Advancell 23
Biofrontera AG 24
Clinuvel Pharmaceuticals Limited 25
Digna Biotech, S.L. 26
Dolorgiet Gmbh & Co. Kg 27
Foamix Pharmaceuticals Ltd. 28
G&E Herbal Biotechnology Co., Ltd. 29
Galderma S.A. 30
Kinex Pharmaceuticals, LLC 31
LEO Pharma A/S 32
Novartis AG 33
Novelix Pharmaceuticals, Inc. 34
Promius Pharma, LLC 35
RestorGenex Corporation 36
Spherium Biomed S.L. 37
Actinic (Solar) Keratosis – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
854-A – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ACT-01 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AD-17137 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
afamelanotide – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AK-3012 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
aminolevulinic acid hydrochloride – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ANs-40 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ANS-401 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ANS-403 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CUV-9900 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
disitertide – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
imiquimod – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
KX-01 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
LEO-43204 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
LFX-453 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NVX-207 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
P-529 – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Recombinant Peptide for Dermatology, Immunology and Oncology – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
resiquimod – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecules to Activate Protein Kinase C for Dermatology and Cancer – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SP-12054 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SRT-100 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
sulindac + hydrogen peroxide – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Actinic (Solar) Keratosis – Recent Pipeline Updates 77
Actinic (Solar) Keratosis – Dormant Projects 85
Actinic (Solar) Keratosis – Discontinued Products 87
Actinic (Solar) Keratosis – Product Development Milestones 88
Featured News & Press Releases 88
Jan 26, 2015: Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz 88
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 88
Nov 26, 2014: Further Progress In International Approval Processes Of Biofrontera’s Ameluz 89
Oct 24, 2014: Europe Approves Novel Australian Drug Developed for Rare Sun Disease 89
Oct 08, 2014: US Regulatory Authority Gives Green Light To Proposed Approach Towards Approval Of Ameluz In The USA 90
Oct 02, 2014: Clinical Program For US Approval Of Ameluz Approaches Completion: Studies Confirm Excellent Efficacy And Safety 91
Aug 21, 2014: Biofrontera AG: Pre-NDA meeting scheduled with FDA for the approval of Ameluz and B-RhodoLED 92
Aug 20, 2014: Biofrontera files litigation against former supplier 92
Aug 11, 2014: Ameluz has passed first stage in approval process in Israel 93
Aug 06, 2014: Biofrontera AG: First Ameluz Sales In Central Eastern European Region 93
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96